Participants (n = 2493) | Seropositive participants (n = 242) | Seroprevalencea % (95% CI) | OR (95% CI) | |
---|---|---|---|---|
COVID-19 diagnosis (n = 2493): | ||||
-No | 2373 | 144 | 6.4 (4.7–8.8) | Ref |
-Yes | 120 | 98 | 68.8 (43.5–86.3) | 32.0 (10.7–96.3) |
COVID-19 hospitalization (n = 120): | ||||
-No | 109 | 88 | 69.5 (50.8–83.4) | Ref |
-Yes | 11 | 10 | 59.3 (43.7–73.3) | 0.6 (0.2–1.8) |
Contact with confirmed cases (n = 2492): | ||||
-No | 2196 | 135 | 7.4 (5.3–10.2) | Ref |
-Yes (≥ 1 person) | 296 | 107 | 31.2 (20.2–44.8) | 5.7 (3.0–10.9) |
Exposure site (n = 296): | ||||
-At home | 197 | 82 | 42.1 (21.1–58.7) | 3.9 (1.1–13.2) |
-Work/small gatherings/others | 99 | 25 | 15.8 (6.3–34.5) | Ref |
Quarantine (n = 296): | ||||
-No | 123 | 32 | 21.9 (10.9–39.1) | Ref |
-Yes | 173 | 75 | 41.0 (24.9–59.3) | 2.5 (0.9–7.3) |
Any symptom:b | ||||
-No | 1841 | 89 | 5.2 (3.5–7.7) | Ref |
-Yes | 652 | 153 | 23.6 (17.1–31.6) | 5.6 (3.03–9.4) |
Number of symptoms: | ||||
-None | 1841 | 89 | 5.2 (3.5–7.7) | Ref |
-1–2 symptoms | 275 | 32 | 19.1 (9.8–33.9) | 4.3 (1.8–10.0) |
-2–3 symptoms | 195 | 46 | 19.6 (11.5–31.2) | 4.4 (2.1–9.2) |
-≥ 5 symptoms | 182 | 75 | 38.1 (24.6–53.8) | 11.2 (5.6–22.3) |
Seek medical care (n = 651): | ||||
-No | 399 | 64 | 17.7 (11.5–26.1) | Ref |
-Yes | 252 | 89 | 32.2 (21.5–45.1) | 2.21 (1.1–4.4) |